Product Description
a new anticancer drug in subjects with advanced solid tumors. an Orally Bioavailable Heat Shock Protein 90 Inhibitor (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01288430)
Mechanisms of Action: HSP90 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Daiichi Sankyo
Company Location: TOKYO M0 103-8426
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01288430 |
DS2248-A-U101 | P1 |
Terminated |
Non-Small-Cell Lung Cancer |
2014-02-13 |
2024-02-16 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|